CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia

Neurology

Volumn 67, Issue 3, 2006, Pages 474-479

  Abdo, W F ^a   Van De Warrenburg, B P C ^a   Munneke, M ^a   Van Geel, W J A ^a   Bloem, B R ^a   Kremer, H P H ^a   Verbeek, M M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; BIOLOGICAL MARKER; HOMOVANILLIC ACID; NEUROFILAMENT PROTEIN; NEUROTRANSMITTER; TAU PROTEIN;

ADULT; AGED; ARTICLE; CEREBELLAR ATAXIA; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HUMAN; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME;

AGE OF ONSET; BIOLOGICAL MARKERS; CEREBELLAR ATAXIA; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NEUROFILAMENT PROTEINS;

EID: 33747033693     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000227891.25592.8c     Document Type: Article

References (32)

1. Abele M, Burk K, Schols L, et al. The aetiology of sporadic adult-onset ataxia. Brain 2002;125:961-968.
2. Schols L, Szymanski S, Peters S, et al. Genetic background of apparently idiopathic sporadic cerebellar ataxia. Hum Genet 2000;107:132-137.
3. Gilman S, Little R, Johanns J, et al. Evolution of sporadic olivoponto-cerebellar atrophy into multiple system atrophy. Neurology 2000;55:527-532.
4. Quinn N. Multiple system atrophy - the nature of the beast. J Neurol Neurosurg Psychiatry 1989;suppl:78-89.
5. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-147.
6. Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 2004;127:2657-2671.
7. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989;94:79-100.
8. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501.
9. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002;125:1070-1083.
10. Klockgether T, Schroth G, Diener HC, Dichgans J. Idiopathic cerebellar-ataxia of late onset - natural-history and MRI morphology. J Neurol Neurosurg Psychiatry 1990;53:297-305.
11. Kaakkola S, Tuomainen P, Mannisto PT, Palo J. Biogenic-amine metabolites in the CSF of patients with late-onset and alcoholic ataxias. Acta Neurol Scand 1993;87:309-311.
12. Higgins JJ, Harvey White JD, Nee LE, Colli MJ, Grossi TA, Kopin IJ. Brain MRI, lumbar CSF monoamine concentrations, and clinical descriptors of patients with spinocerebellar ataxia mutations. J Neurol Neurosurg Psychiatry 1996;61:591-595.
13. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003;18:467-486.
14. Van Geel WJ, de Reus HP, Nijzing H, Verbeek MM, Vos PE, Lamers KJ. Measurement of glial fibrillary acidic protein in blood: an analytical method. Clin Chim Acta 2002;326:151-154.
15. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ. Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000;31:2670-2677.
16. Van Geel WJ, Rosengren LE, Verbeek MM. An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods 2005;296:179-185.
17. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003;278:179-190.
18. Brautigam C, Wevers RA, Jansen RJ, et al. Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem 1998;44:1897-1904.
19. Abdo WF, de Jong D, Hendriks JCM, et al. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov Disord 2004;19:571-579.
20. Ormerod IE, Harding AE, Miller DH, et al. Magnetic resonance imaging in degenerative ataxic disorders. J Neurol Neurosurg Psychiatry 1994;57:51-57.
21. Fuchs E, Cleveland DW. A structural scaffolding of intermediate filaments in health and disease. Science 1998;279:514-519.
22. Yazawa I, Giasson BI, Sasaki R, et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 2005;45:847-859.
23. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:402-404.
24. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013-2018.
25. Holmberg B, Johnels B, Ingvarsson P, Eriksson B, Rosengren L. CSF-neurofilament and levodopa test combined with discriminant analysis may contribute to the differential diagnosis of parkinsonian syndromes. Parkinsonism Relat Disord 2001;8:23-31.
26. Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord 1998;13:70-77.
27. Botez MI, Young SN. Biogenic amine metabolites and thiamine in cerebrospinal fluid in heredo-degenerative ataxias. Can J Neurol Sci 2001;28:134-140.
28. Benarroch EE, Smithson IL, Low PA, Parisi JE. Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure. Ann Neurol 1998;43:156-163.
29. Mathias CJ, Williams AC. The Shy-Drager syndrome (and multiple system atrophy). In: Calne DB, ed. Neurodegenerative diseases. Philadelphia: WB Saunders, 1994:743-767.
30. Polinsky RJ, Jimerson DC, Kopin IJ. Chronic autonomic failure: CSF and plasma 3-methoxy-4-hydroxyphenylglycol. Neurology 1984;34:979-983.
31. Wenning GK, Ben SY, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117:835-845.
32. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002;125:1070-1083.